RESEARCH · BPC-157 · TB-500 · GHK-CU
GLOW BLEND 70mg: What the Research Says About BPC-157, TB-500 and GHK-Cu
GLOW BLEND 70mg is a three-component research blend supplied in a single lyophilized vial: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg, 70mg total labelled content. Each component has its own research literature, mostly from cell and animal models. Research on the components together is far more limited. This article summarises what has been published on each one, what is known about combinations, and what remains open.
What is in the vial
- BPC-157: a 15-amino-acid pentadecapeptide described as a partial sequence of “body protection compound”, originally isolated from human gastric juice [1].
- TB-500: a synthetic peptide whose key ingredient is the N-terminally acetylated sequence Ac-LKKTETQ, which corresponds to residues 17–23 of thymosin β4 [2,3].
- GHK-Cu: the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide found in human blood [4,5].
BPC-157: what preclinical research reports
- Tendon cells. In rat Achilles tendon explants, BPC-157 accelerated the outgrowth of tendon fibroblasts. It did not directly change fibroblast proliferation, but it increased cell survival under hydrogen-peroxide stress and dose-dependently increased fibroblast migration and spreading, with activation of the FAK–paxillin pathway [1].
- Blood-vessel formation. BPC-157 increased vessel density in the chick chorioallantoic membrane assay and endothelial tube-formation assays, accelerated blood-flow recovery in a rat hind-limb ischaemia model, and increased VEGFR2 expression and VEGFR2–Akt–eNOS signalling in endothelial cells [6].
- Broad animal literature. The group that has published most on BPC-157 reviews gastrointestinal, tendon, ligament, muscle and bone injury models and argues that the peptide acts through angiogenic pathways [7].
Independent reviewers are more cautious. A 2019 review noted that most studies have used small rodent models, that efficacy is yet to be confirmed in humans, and that only a handful of research groups have studied the peptide in depth [8]. A 2025 systematic review identified 36 eligible studies: 35 preclinical and one small retrospective clinical report. It found no clinical safety data and noted that BPC-157 lacks FDA approval and is banned in professional sports [9].
TB-500 and thymosin β4: not the same molecule
Thymosin β4 is a naturally occurring actin-sequestering peptide released by platelets, macrophages and many other cells after injury [10,11]. Studies of the full-length peptide include:
- Skin wounds. In a rat full-thickness wound model, thymosin β4 increased re-epithelialisation by 42% over saline at day 4 and by up to 61% at day 7, and stimulated keratinocyte migration in vitro [12].
- Heart. Thymosin β4 formed a complex with PINCH and integrin-linked kinase, activating the survival kinase Akt. After coronary artery ligation in mice it enhanced early myocyte survival and improved cardiac function [13].
TB-500, however, is not full-length thymosin β4. Analytical chemists identified the acetylated 17–23 fragment (Ac-LKKTETQ) in TB-500 [2], and a horse-racing laboratory describes TB-500 as a veterinary preparation containing that synthetic fragment and developed doping-control methods to detect it [3]. Findings for full-length thymosin β4 therefore cannot simply be assumed to apply to TB-500.
GHK-Cu in brief
GHK-Cu stimulated collagen synthesis in fibroblast cultures at very low concentrations [14]. In a rat wound-chamber model, it increased wound tissue, type I collagen and glycosaminoglycans and shifted small proteoglycan expression toward decorin [15]. Pickart’s review groups its reported activities into repair-cell attraction, anti-inflammatory and antioxidant actions, increased matrix-protein synthesis, and increased fibroblast and keratinocyte proliferation [4]. For more detail, see our GHK-Cu 50mg research overview.
Is there research on the combination?
A 2026 rat study compared BPC-157, TB-500 and the two together after Achilles tendon transection and repair. After four weeks, the TB-500 group showed a statistically significant biomechanical advantage over controls, and both TB-500 and the combination group had better histological tendon scores. The combination, however, did not confer additional benefits compared with either peptide alone. The authors describe the study as exploratory [16].
In our search of PubMed in October 2026 we found no peer-reviewed study testing all three components of this blend (BPC-157 + TB-500 + GHK-Cu) together. A 2026 review of unapproved peptides in sports medicine also concluded that rigorous human safety data for such compounds are scarce and noted the potential for serious harm [17].
What remains unknown
- Whether the three components interact in any way (additively, redundantly or antagonistically) in a given laboratory model. The only two-peptide study found no added benefit [16].
- How far results for full-length thymosin β4 carry over to the TB-500 fragment [2,3].
- How robust the BPC-157 literature is, given that it comes largely from small rodent studies and a small number of groups [8,9].
- Formulation questions such as stability and analytical separation of three peptides in one vial. These are worth considering when designing experiments.
General laboratory storage background
Laboratories should always follow the product label, any batch documentation and their own approved procedures. As general background, peptide suppliers’ technical guides describe broadly similar practice for lyophilized (freeze-dried) peptides:
- Dry, dark and cold. Store lyophilized peptides away from heat, light and moisture; about −20 °C is commonly recommended for longer-term storage [18,19].
- Moisture. Sequences rich in Asp, Glu, Lys, Arg or His tend to absorb moisture and are best kept in a desiccator in a tightly capped vial [18]. All three components contain lysine.
- Avoid condensation and repeated thawing. Let a cold vial reach room temperature before opening and avoid freeze–thaw cycles [19].
- Solutions are short-lived. Peptides in solution have a much shorter shelf life than the dry powder [18].
This is general laboratory information, not a protocol, and it contains no instructions for human use.
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: one lyophilized vial with the labelled composition BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg (70mg total), C$136 per vial (CAD, before tax), for laboratory research only. Related single products: GHK-Cu 50mg (C$49) and the two-component BPC-157 + TB-500 10mg (5mg + 5mg, C$89).
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Codes: WELCOME10 takes 10% off eligible orders below C$400; PURIX20 takes 20% off eligible orders of C$400 or more before discount and tax. One offer per order; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672 · doi:10.1152/japplphysiol.00945.2010
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. PubMed 18644225 · doi:10.1163/156856208784909435
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PubMed 25302294 · PMC4180391 · doi:10.1155/2014/151479
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966 · doi:10.1007/s00109-016-1488-y
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PubMed 29998800 · doi:10.2174/1381612824666180712110447
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed 30915550 · doi:10.1007/s00441-019-03016-8
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed 40756949 · PMC12313605 · doi:10.1177/15563316251355551
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. PubMed 16099219 · doi:10.1016/j.molmed.2005.07.004
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed 22074294 · doi:10.1517/14712598.2012.634793
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed 10469335 · doi:10.1046/j.1523-1747.1999.00708.x
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145 · doi:10.1038/nature03000
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PubMed 3169264 · doi:10.1016/0014-5793(88)80509-x
- Siméon A, Wegrowski Y, Bontemps Y, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-8. PubMed 11121126 · doi:10.1046/j.1523-1747.2000.00166.x
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926 · doi:10.52312/jdrs.2026.2951
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- GenScript. Peptide Storage and Handling Guidelines (technical resource). GenScript
- AAPPTec. Handling and Storage of Peptides — FAQ (technical resource). AAPPTec